Clinical trials: sponsored by Boehringer Ingelheim
Healthy, Hepatic Insufficiency
A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems
The primary objective of this trial is the evaluation of safety and tolerability in patients with mild to moderate hepatic impairment [Child-Turcotte-Pugh (CTP) classification A and B] over different dose regimes of BI 685509…
- Trial name
- NCT03842761
- Testing
- BI 685509
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
The main objectives of this study are: Determine the difference in change from baseline in Six Minute Walk Distance (6MWD) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with…
- Trial name
- NCT03717012
- Testing
- Nintedanib, Pulmonary rehabilitation program
- Where
- 19 sites in United States
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Healthy
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days
The primary objective of this trial is to investigate the safety and tolerability of BI 1467335 in healthy male and female subjects following oral administration of multiple rising doses over 28 days.
- Trial name
- NCT02733627
- Testing
- BI 1467335
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects
The primary objective of this trial is to investigate the relative bioavailability of BI 1467335, given as film-coated tablet compared to BI 1467335, given as oral solution.
- Trial name
- NCT02999191
- Testing
- BI 1467335 (Treatment A), BI 1467335 (Treatment B), BI 1467335 (Treatment C)
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated
The primary objective of the current study is to investigate the safety and tolerability of BI 1467335 in healthy Japanese male subjects following oral administration of multiple rising doses The Caucasian group will receive…
- Trial name
- NCT03159455
- Testing
- BI 1467335
- Where
- 2 sites in Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetic Retinopathy
A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.
The main objective is to evaluate ocular and systemic safety and tolerability of BI 1467335 as well as whether BI 1467335 monotherapy has a potential to improve retinal lesions in patients with moderately severe Non-proliferative…
- Trial name
- ROBIN (NCT03238963)
- Testing
- BI 1467335
- Where
- 35 sites in United States, Austria and 6 more
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1
The primary objective of this trial is to assess the efficacy, safety and pharmacokinetics of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler versus placebo in adolescents and adult patients with cystic…
- Trial name
- NCT04059094
- Testing
- BI 1265162
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 52 people
- Sponsor
- Boehringer Ingelheim
Renal Insufficiency, Healthy
A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body
The primary objective of the current study is to investigate the influence of moderate renal impairment on the pharmacokinetics of multiple doses in comparison to a matched control group with normal renal function.
- Trial name
- NCT03302091
- Testing
- BI 1467335
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure
The main objective of the study is investigate the effect of escalating doses of oral tyramine on systolic blood pressure (SBP) at baseline and following an oral treatment with BI 1467335 up to 39 days at a low or high dose once…
- Trial name
- NCT03979820
- Testing
- BI 1467335, Phenelzine sulfate, Tyramine
- Where
- Netherlands
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Regulatory Request NIS in Korea
To monitor the safety profile and effectiveness of JARDIANCE DUO® in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting
- Trial name
- NCT03642717
- Testing
- JARDIANCE DUO®
- Where
- 20 sites in South Korea
- Volunteers
- 658 people
- Sponsor
- Boehringer Ingelheim
Age-related Macular Degeneration
Global Atrophie Biomarker Evaluation Study (GABiE)
To investigate the use of microperimetry and SS-OCT in assessing the natural changes of retinal sensitivity and anatomy in the perilesional zone of geographic atrophy areas in patients with dry age-related macular degeneration.
- Trial name
- GABiE (NCT03935126)
- Testing
- Diagnostics
- Where
- 2 sites in United States, Switzerland
- Volunteers
- 3 people
- Sponsor
- Boehringer Ingelheim
Obesity
A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight
The primary objective of this trial is to investigate safety and tolerability of BI 1356225 in male and female patients with overweight and obesity following oral administration of multiple rising doses per day over 28 days.
- Trial name
- NCT04447261
- Testing
- BI 1356225
- Where
- Germany
- Volunteers
- 87 people
- Sponsor
- Boehringer Ingelheim
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
- Trial name
- NCT03057977
- Testing
- Empagliflozin
- Where
- 520 sites in United States, Argentina and 18 more
- Volunteers
- 3,730 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus
To monitor the safety profile and effectiveness of Empagliflozin in Korea patients with type 2 diabetes mellitus in a routine clinical practice setting
- Trial name
- NCT02848833
- Testing
- JARDIANCE 10mg, JARDIANCE 25mg
- Where
- South Korea
- Volunteers
- 3,368 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
Examine the risk of cardiovascular events (cardiac arrhythmia or myocardial ischemia) or all-cause mortality in Chronic Obstructive Pulmonary Disease (COPD) patients who are new users of Olodaterol or other LABAs available for…
- Trial name
- NCT03405363
- Where
- Denmark
- Volunteers
- 65,406 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other
Investigate the effect of steady state exposures of memantine on the steady-state pharmacokinetics of BI 425809 and vice versa in healthy subjects.
- Trial name
- NCT03988803
- Testing
- BI 425809, Memantine
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Fibrosis
Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan
This is a non-interventional, multi-center study to collect data from patients with idiopathic pulmonary fibrosis (IPF) in clinical practice in Taiwan.
- Trial name
- NCT03242759
- Testing
- nintedanib, pirfenidone
- Where
- 10 sites in Taiwan
- Volunteers
- 101 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.
This non-Interventional, descriptive, cross-sectional cohort and multicentre study will be conducted with COPD patients attended at Spanish Primary Care offices.
- Trial name
- NCT03611777
- Testing
- Inhaled corticosteroid
- Where
- 169 sites in Spain
- Volunteers
- 901 people
- Sponsor
- Boehringer Ingelheim
Stroke, Atrial Fibrillation
GLORIA-AF Registry Program - Second and Third Phases
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
- Trial name
- NCT01468701
- Where
- 666 sites in United States, Argentina and 19 more
- Volunteers
- 37,235 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes
Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals
- Trial name
- EDCOS (NCT04098575)
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 9,571 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.